β,β-Dimethylacrylshikonin (Synonyms: Isoarnebin I)

目录号: HY-N5112B 纯度: 99.30%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

β,β-Dimethylacrylshikonin (Isoarnebin I) 是一种萘醌衍生物，可从紫草中分离得到。β,β-Dimethylacrylshikonin 通过 PI3K 依赖性途径诱导 eNOS、VEGF 和 HIF-1α 表达，从而促进血管生成。β,β-Dimethylacrylshikonin 抑制 Notch-1 活化。β,β-Dimethylacrylshikonin 抑制肿瘤细胞增殖，诱导肿瘤细胞凋亡 (Apoptosis)，抑制肿瘤生长。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

β,β-Dimethylacrylshikonin Chemical Structure

CAS No. : 24502-79-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥550	In-stock
10 mg	￥950	In-stock
25 mg	￥2000	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of β,β-Dimethylacrylshikonin:

β,β-Dimethylacrylalkannin In-stock

MCE 顾客使用本产品发表的 1 篇科研文献

•Phytomedicine. 2023 Mar 15;114:154769. [Abstract]

β,β-Dimethylacrylshikonin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIF/HIF Prolyl-Hydroxylase 亚型特异性产品:

查看所有亚型

HIF-1α HIF

查看 NO Synthase 亚型特异性产品:

查看所有亚型

nNOS iNOS eNOS

查看 Bcl-2 Family 亚型特异性产品:

查看所有亚型

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

生物活性
纯度 & 产品资料
参考文献

生物活性

β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative that can be isolated from Lithospermum erythrorhizon Sieb. et Zucc. β,β-Dimethylacrylshikonin promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. β,β-Dimethylacrylshikonin inhibits Notch-1 activation. β,β-Dimethylacrylshikonin inhibtis tumor cell proliferation, induces tumor cell apoptosis, and inhibits tumor growth^[1]^[2]^[3]^[4].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
B16-F0	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31961147]
B16-F0	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31961147]
CCRF-CEM	IC₅₀	1.9 μM Compound: 3	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 22530779]
HCT-116	IC₅₀	20 μM Compound: 3	Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay	[PMID: 22530779]
MDA-MB-231	IC₅₀	23.2 μM Compound: 3	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay	[PMID: 22530779]
MRC5	IC₅₀	2.4 μM Compound: 3	Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay	[PMID: 22530779]
MRC5	IC₅₀	9.5 μM Compound: DMAS	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel1	IC₅₀	1 μM Compound: DMAS	Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel1	IC₅₀	1.1 μM Compound: DMAS	Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel1	IC₅₀	1.9 μM Compound: DMAS	Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	1.7 μM Compound: DMAS	Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	2.3 μM Compound: DMAS	Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	5.1 μM Compound: DMAS	Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	7.2 μM Compound: 1-76	Antitumor activity against human MUG-Mel2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antitumor activity against human MUG-Mel2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 35367708]
SBcl2	IC₅₀	1.1 μM Compound: 1-76	Antitumor activity against human SBcl2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antitumor activity against human SBcl2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 35367708]
SBcl2	IC₅₀	1.1 μM Compound: 3	Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay	[PMID: 22530779]
SBcl2	IC₅₀	1.1 μM Compound: DMAS	Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
SBcl2	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
SBcl2	IC₅₀	1.9 μM Compound: DMAS	Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
U-251	IC₅₀	30.8 μM Compound: 3	Cytotoxicity against human U251 cells after 72 hrs by XTT assay Cytotoxicity against human U251 cells after 72 hrs by XTT assay	[PMID: 22530779]
WM164	IC₅₀	2.4 μM Compound: DMAS	Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM164	IC₅₀	3 μM Compound: DMAS	Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM164	IC₅₀	3.8 μM Compound: DMAS	Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM164	IC₅₀	8.3 μM Compound: 1-76	Antitumor activity against human WM164 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antitumor activity against human WM164 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 35367708]
WM164	IC₅₀	8.3 μM Compound: 3	Cytotoxicity against human WM164 cells after 72 hrs by XTT assay Cytotoxicity against human WM164 cells after 72 hrs by XTT assay	[PMID: 22530779]
WM793	IC₅₀	0.7 μM Compound: DMAS	Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM793	IC₅₀	0.8 μM Compound: DMAS	Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM793	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]

体外研究
(In Vitro)

β,β-Dimethylacrylshikonin (0-80 μM，24 或 48 小时) 抑制TNBC 细胞 G2/M 期转变并抑制增殖^[3]。
β,β-Dimethylacrylshikonin (0-10 μM，24 小时) 诱导线粒体依赖性细胞凋亡并通过拮抗上皮-间质转化减少 TNBC 细胞迁移^[3]。
β,β-Dimethylacrylshikonin (0-30 μg/mL，48 小时) 抑制 SGC-7901 细胞中 Notch-1 活化、Jagged-1 及下游靶标 Hes-1 表达^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[3]

Cell Line:	TNBC cells: MDA-MB-231, BT-549, HS578T cells
Concentration:	2.5, 5, 10 μM
Incubation Time:	24 h
Result:	Increased the proportion of late apoptotic and necrotic cells. Downregulated Bcl2, and increased Bax expression. Increased the level of cleaved-caspase3.

体内研究
(In Vivo)

β,β-Dimethylacrylshikonin (0.1% PBS 悬浮液，局部涂抹在伤口上，每天使用 12 天) 可加速大鼠氢化可的松 (HY-N0583) 引起的伤口愈合障碍^[2]。
β,β-Dimethylacrylshikonin (1 或 2 mg/kg，腹腔注射，隔天) 通过抑制 STAT3 磷酸化来抑制 BT-549 异种移植小鼠模型中的肿瘤生长^[3]。
β,β-Dimethylacrylshikonin (0.5-1.5 mg/kg，腹腔注射) 可抑制 MFC 胃异种移植小鼠模型中的肿瘤生长^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hydrocortisone induced impaired wound healing in cutaneous punch wound rat model^[1]
Dosage:	0.1% suspension in PBS; Hydrocortisone (30 mg/kg, i.m., daily, 11d)
Administration:	applied topically on wounds, daily for 11 days
Result:	HE staining: Showed more number of cells and vessels in the granulation tissue, and enhanced epidermal regeneration and collagen synthesis. Enhanced the formation and migration of the epidermis over the wound. Increased gap closure during normal and impaired healing

Animal Model:	Athymic BALB/c nu/nu female mice (6- 8 week-old, 18-22 g), BT-549 cells were injected subcutaneously into the right thigh root of mice^[3].
Dosage:	1 or 2 mg/kg
Administration:	i.p., on alternate days
Result:	Decreased the expression of Ki67, CyclinB1 and CDK1 in tumor. Up-regulated Bax expression and down-regulated Bcl-2 expression. Increased the expression of E-cadherin and decreased N-cadherin and vimentin. Decreased the level of p-STAT3 without changing total STAT3 levels.

分子量

370.40

Formula

C₂₁H₂₂O₆

CAS 号

24502-79-2

性状

固体

颜色

Brown to reddish brown

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 12.5 mg/mL (33.75 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6998 mL	13.4989 mL	26.9978 mL
5 mM	0.5400 mL	2.6998 mL	5.3996 mL
10 mM	0.2700 mL	1.3499 mL	2.6998 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.30%

选择批次：

Data Sheet (629 KB) SDS (762 KB)

COA (199 KB) LCMS (88 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Zeng Z, et al. Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. Int J Mol Med. 2015 Sep;36(3):685-97. [Content Brief]

[2]. Sidhu GS, et al. Arnebin-1 accelerates normal and hydrocortisone-induced impaired wound healing. J Invest Dermatol. 1999 Nov;113(5):773-81. [Content Brief]

[3]. Wu Z, et al. β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis. Phytomedicine. 2023 Jun;114:154769. [Content Brief]

[4]. Zhen-Jun S, et al. β,β-Dimethylacrylshikonin exerts antitumor activity via Notch-1 signaling pathway in vitro and in vivo. Biochem Pharmacol. 2012 Aug 15;84(4):507-12.

β,β-Dimethylacrylshikonin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6998 mL	13.4989 mL	26.9978 mL	67.4946 mL
	5 mM	0.5400 mL	2.6998 mL	5.3996 mL	13.4989 mL
	10 mM	0.2700 mL	1.3499 mL	2.6998 mL	6.7495 mL
	15 mM	0.1800 mL	0.8999 mL	1.7999 mL	4.4996 mL
	20 mM	0.1350 mL	0.6749 mL	1.3499 mL	3.3747 mL
	25 mM	0.1080 mL	0.5400 mL	1.0799 mL	2.6998 mL
	30 mM	0.0900 mL	0.4500 mL	0.8999 mL	2.2498 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

β,β-Dimethylacrylshikonin (Synonyms: Isoarnebin I)

Customer Review

Other Forms of β,β-Dimethylacrylshikonin:

MCE 顾客使用本产品发表的 1 篇科研文献

β,β-Dimethylacrylshikonin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIF/HIF Prolyl-Hydroxylase 亚型特异性产品:

查看 NO Synthase 亚型特异性产品:

查看 Bcl-2 Family 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

β,β-Dimethylacrylshikonin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

β,β-Dimethylacrylshikonin (Synonyms: Isoarnebin I)

Customer Review

Other Forms of β,β-Dimethylacrylshikonin:

β,β-Dimethylacrylshikonin 相关抗体

MCE 顾客使用本产品发表的 1 篇科研文献

β,β-Dimethylacrylshikonin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIF/HIF Prolyl-Hydroxylase 亚型特异性产品:

查看 NO Synthase 亚型特异性产品:

查看 Bcl-2 Family 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

β,β-Dimethylacrylshikonin 相关抗体:

摩尔计算器

稀释计算器

β,β-Dimethylacrylshikonin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z